GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
JPS4921148B1
(el)
|
1970-12-28 |
1974-05-30 |
|
|
JPS4921149B1
(el)
|
1970-12-28 |
1974-05-30 |
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
EP0489925B1
(en)
|
1990-07-03 |
1996-06-12 |
Mitsui Petrochemical Industries, Ltd. |
Pyrimidine compound and pharmaceutically acceptable salt thereof
|
AU692090B2
(en)
|
1995-04-13 |
1998-05-28 |
Taiho Pharmaceutical Co., Ltd. |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
EP1020462B1
(en)
|
1997-07-24 |
2004-02-11 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compounds and antitumor agent containing the same as active ingredient
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンa3拮抗剤
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
ES2193607T3
(es)
|
1998-01-16 |
2003-11-01 |
Hoffmann La Roche |
Derivados de benzosulfona .
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
JP4533534B2
(ja)
|
1998-06-19 |
2010-09-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
グリコーゲンシンターゼキナーゼ3のインヒビター
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
AU768201B2
(en)
|
1999-01-22 |
2003-12-04 |
Amgen, Inc. |
Kinase inhibitors
|
WO2001000207A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
SIN KINASE INHIBITOR COMPOUNDS
|
EP1206265B1
(en)
|
1999-06-30 |
2003-11-12 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
IL147395A0
(en)
|
1999-07-15 |
2002-08-14 |
Pharmacopeia Inc |
Bradykinin b1 receptor antagonists
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
WO2001060816A1
(en)
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
AU2001242629B2
(en)
|
2000-03-29 |
2005-08-11 |
Cyclacel Limited |
2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
|
EP1277738B1
(en)
|
2000-04-27 |
2011-03-30 |
Astellas Pharma Inc. |
Condensed heteroaryl derivatives
|
NZ522217A
(en)
|
2000-04-28 |
2004-04-30 |
Tanabe Seiyaku Co |
Cyclic compounds
|
WO2002000647A1
(en)
|
2000-06-23 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
KR100816769B1
(ko)
|
2000-09-06 |
2008-03-26 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
글리코겐 합성효소 키나아제 3의 억제제
|
US6638926B2
(en)
|
2000-09-15 |
2003-10-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
CA2432303C
(en)
|
2000-12-21 |
2010-04-13 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
AU2002258400A1
(en)
|
2001-02-16 |
2002-08-28 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
CA2450934A1
(en)
|
2001-06-19 |
2002-12-27 |
Marco Dodier |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
ATE466580T1
(de)
|
2002-03-15 |
2010-05-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
AU2003225800A1
(en)
|
2002-03-15 |
2003-09-29 |
Hayley Binch |
Azolylaminoazine as inhibitors of protein kinases
|
EP1485380B1
(en)
|
2002-03-15 |
2010-05-19 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines as inhibitors of protein kinases
|
DE60314603T2
(de)
|
2002-03-15 |
2008-02-28 |
Vertex Pharmaceuticals Inc., Cambridge |
Zusammensetzungen brauchbar als protein-kinase-inhibitoren
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
EP1546115A4
(en)
|
2002-09-27 |
2010-08-04 |
Merck Sharp & Dohme |
SUBSTITUTED PYRIMIDINES
|
AU2003288925A1
(en)
|
2002-10-08 |
2004-05-04 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
ATE527250T1
(de)
|
2002-11-21 |
2011-10-15 |
Novartis Ag |
2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
|
CA2514733A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
CN101468965A
(zh)
|
2003-03-24 |
2009-07-01 |
默克公司 |
联芳基取代的6元杂环钠通道阻滞剂
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
AU2004230928B2
(en)
|
2003-04-09 |
2010-12-02 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
CA2531490A1
(en)
|
2003-07-15 |
2005-02-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
|
CA2531619A1
(en)
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
EP1742634B1
(en)
|
2004-04-13 |
2010-10-27 |
ICAgen, Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
EP1827434B1
(en)
*
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
US20080045525A1
(en)
|
2004-12-13 |
2008-02-21 |
Rajagopal Bakthavatchalam |
Piperazinyl-Pyridine Analogues
|
JP2008523156A
(ja)
|
2004-12-13 |
2008-07-03 |
ニューロジェン・コーポレーション |
置換ビアリール類縁体
|
JP5124285B2
(ja)
|
2004-12-28 |
2013-01-23 |
キネックス ファーマシューティカルズ, エルエルシー |
細胞増殖性障害を処置する組成物および方法
|
WO2006078992A2
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
US20100130473A1
(en)
|
2005-02-25 |
2010-05-27 |
Marc Geoffrey Hummersone |
Compounds
|
JP2008536950A
(ja)
|
2005-04-18 |
2008-09-11 |
ニューロジェン・コーポレーション |
置換ヘテロアリールのcb1拮抗薬
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
JP2009523161A
(ja)
|
2006-01-11 |
2009-06-18 |
アストラゼネカ アクチボラグ |
モルホリノピリミジン誘導体と療法におけるその使用
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007120897A2
(en)
*
|
2006-04-13 |
2007-10-25 |
The Trustees Of Columbia University In The City Of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
AR064571A1
(es)
|
2006-12-28 |
2009-04-08 |
Basf Ag |
Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
|
CA2675558A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
JP2010533158A
(ja)
|
2007-07-09 |
2010-10-21 |
アストラゼネカ アクチボラグ |
化合物類−945
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
US20110033453A1
(en)
|
2008-03-05 |
2011-02-10 |
Carlos Garcia-Echeverria |
Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
|
US20110020338A1
(en)
|
2008-03-26 |
2011-01-27 |
Carlos Garcia-Echeverria |
5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes
|
US20110053907A1
(en)
|
2008-03-27 |
2011-03-03 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
TW200948362A
(en)
|
2008-04-09 |
2009-12-01 |
Mitsubishi Tanabe Pharma Corp |
New compounds and their uses
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
EP2349275B1
(en)
|
2008-10-31 |
2017-03-08 |
Novartis AG |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
US8513242B2
(en)
|
2008-12-12 |
2013-08-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
DK2394999T3
(da)
|
2009-02-06 |
2014-05-05 |
Nippon Shinyaku Co Ltd |
Aminopyrazinderivat og medicin
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
CA2755394C
(en)
|
2009-03-13 |
2021-10-19 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
PT2432767E
(pt)
|
2009-05-19 |
2013-07-25 |
Dow Agrosciences Llc |
Compostos e métodos para controlo de fungos
|
EP2532659A1
(en)
|
2009-07-07 |
2012-12-12 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
AR077695A1
(es)
|
2009-08-04 |
2011-09-14 |
Schering Corp |
Derivados de pirimidina como inhibidores del factor ixa
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
WO2011031896A2
(en)
|
2009-09-09 |
2011-03-17 |
Avila Therapeutics, Inc. |
Pi3 kinase inhibitors and uses thereof
|
WO2011072174A1
(en)
|
2009-12-09 |
2011-06-16 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
AU2011278998B2
(en)
|
2010-07-16 |
2016-06-09 |
Les Laboratoires Servier |
Therapeutically active compositions and their method of use
|
CN104945373A
(zh)
|
2010-10-01 |
2015-09-30 |
诺华有限公司 |
制造嘧啶衍生物的方法
|
NZ718514A
(en)
|
2010-10-18 |
2017-10-27 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
CA2826387A1
(en)
|
2011-02-11 |
2012-08-16 |
Dana Farber Cancer Institute, Inc. |
Method of inhibiting hamartoma tumor cells
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
US20140213583A1
(en)
|
2011-09-01 |
2014-07-31 |
Novartis Ag |
PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
CA2851082A1
(en)
|
2011-10-06 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
1,3-substituted azetidine pde10 inhibitors
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AU2013263043B2
(en)
*
|
2012-05-16 |
2016-06-16 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
US20150157645A1
(en)
|
2012-06-06 |
2015-06-11 |
Samit Hirawat |
Combination of a 17-alpha-hydroxylase (c17,20-lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
|
CA2879704A1
(en)
|
2012-08-16 |
2014-02-20 |
Novartis Ag |
Combination of pi3k inhibitor and c-met inhibitor
|
MX360703B
(es)
|
2012-10-23 |
2018-11-14 |
Novartis Ag |
Proceso mejorado para la elaboración de 5-(2, 6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amin a.
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
CN105263929B
(zh)
|
2013-03-14 |
2018-08-28 |
诺华股份有限公司 |
作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
|
KR20150127197A
(ko)
|
2013-03-14 |
2015-11-16 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|